Carbapenamase OXA-23 like-producing Acinetobacter baumanii epidemic outbreak in a hospitalization unit
e202102027
Keywords:
Acinetobacter baumannii, Multi-drug-resistant, Outbreak, Cross Infection, HospitalAbstract
Background: Despite its great ubiquity and morbidity and mortality, the scientific evidence on the hospital control of multiresistant Acinetobacter baumanii (ABMR) outside the Intensive Care Units in Spain is scarce. The objective was to describe an epidemic outbreak by MRAB and analyze the effectiveness of the actions carried out.
Methods: Prospective observational study of admitted-rotated patients in a multipathological control at the University Hospital of Guadalajara, Spain, during the outbreak (September 20-November 3, 2017); using Mambrino Electronic Health Record. A genetic study of the resistance mechanism and molecular characterization of the strains were carried out. Frequency measurements were estimated, with subsequent comparative analysis of cases vs controls.
Results: The median age of the study population (N=138) was 83.2 years (Interquartile Range [IR]=69.7-90.1). There were 3 cases of ABMR infection among them. Thirteen percent required issolation, 17% because of MRAB. The MRAB incidence was 2.2 cases/100 admitted-rotated (mortality rate=33%). The excess stay for cases was 17±4.3 (95%CI=8.5-25.6), with an incidence density of 3 cases/10³ days. The responsible strain was carbapenemase OXA-23. We found a single case in the colonization study of contacts. No MRAB was isolated from environmental samples.
Conclusions: Along with epidemiological research, coordination and compliance with precautions; prompt identification and management of an outbreak are crucial to minimize the colonization pressure and to stop dissemination.
Downloads
References
Hernández-Torres A, García-Vázquez E, Gómez J, Canteras M, Ruiz J, Fernández-Rufete A et al. Carbapenem and multidrug-resistant Acinetobacter baumannii colonisation/infection: Epidemiology and factors associated with infection. Med Clin 2010;135:389-96.
World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of new Antibiotics. [Internet](Acceso: 12/08/2018). Disponible en: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1
Grupo de trabajo del E.P. Hospital de Poniente, El Ejido (Almería). Actuación en brotes de infección nosocomial causados por Acinetobacter baumanii multirresistente. Sistema de Vigilancia Epidemiológica de Andalucía (SVEA). [Internet] (Acceso: 30/11/2017). Disponible en: https://es.scribd.com/document/328720319/ACINETOBACTER
Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97–103.
Enoch DA, Summers C, Brown NM, Moore L, Gillham MI, Burnstein RM et al. Investigation and management of an outbreak of multidrug-carbapenemresistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect. 2008;70: 109–18.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
Siegel JD, Rhinehart E, Jackson M, Chiarello L and the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. [Internet] (Acceso: 14 abril 2018). Disponible en: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html
Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P. In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural blaOXA-66 oxacillinase gene. Antimicrb. Agents Chemother., 2009;53:2657–2659.
Tena D, Martínez NM, Oteo J, Sáez D, Vindel A, Azañedo ML et al. Outbreak of multiresistant OXA-24- and OXA-51-producing Acinetobacter baumannii in an internal medicine ward. Jpn J Infect Dis. 2013;66(4):323-6.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Olga Redondo González, Irene Lorenzo Prieto, Juan Cobos López, Clara María Bravo Villaseñor, Nora Mariela Martínez, Jesús Oteo Iglesias
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
